(0.18%) 5 109.19 points
(0.13%) 38 291 points
(0.21%) 15 962 points
(-1.09%) $82.94
(4.84%) $2.02
(0.12%) $2 350.00
(0.12%) $27.57
(4.19%) $960.70
(-0.18%) $0.933
(-0.31%) $10.99
(-0.46%) $0.797
(1.74%) $93.47
@ $9.81
发出时间: 15 Feb 2024 @ 03:26
回报率: -6.58%
上一信号: Feb 14 - 22:30
上一信号:
回报率: 1.82 %
Live Chart Being Loaded With Signals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B...
Stats | |
---|---|
今日成交量 | 65 935.00 |
平均成交量 | 407 914 |
市值 | 904.78M |
EPS | $-0.400 ( 2023-11-13 ) |
下一个收益日期 | ( $-0.410 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.83 |
ATR14 | $0.0340 (0.37%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Chao David M | Sell | 10 385 | Ordinary Shares |
2024-03-31 | Weinhoff Gregory M | Sell | 11 742 | Ordinary Shares |
2024-03-31 | Saha Saurabh | Sell | 36 263 | Ordinary Shares |
2024-03-31 | Hussain Iqbal J | Sell | 7 520 | Ordinary Shares |
2024-03-31 | Bush Tia L | Sell | 6 419 | Ordinary Shares |
INSIDER POWER |
---|
61.95 |
Last 100 transactions |
Buy: 3 998 584 | Sell: 832 725 |
音量 相关性
Centessa Pharmaceuticals 相关性 - 货币/商品
Centessa Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $6.88M |
毛利润: | $6.07M (88.18 %) |
EPS: | $-1.580 |
FY | 2023 |
营收: | $6.88M |
毛利润: | $6.07M (88.18 %) |
EPS: | $-1.580 |
FY | 2022 |
营收: | $0 |
毛利润: | $-130 919 (0.00 %) |
EPS: | $-2.31 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-4.05 |
Financial Reports:
No articles found.
Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。